

Interview Released with Bioceros CSO Ahead of Biosimilars 2017

Competitive pricing of biosimilar drugs will continue to be a major challenge for branded pharmaceuticals

LONDON, ENGLAND, UNITED KINGDOM, July 3, 2017 /EINPresswire.com/ -- SMi Group have released an interview with Bioceros Founder and Chief Scientific Officer, Dr Louis Boon, ahead of his keynote address at the 8th annual [Biosimilars and Biobetters](#) conferences taking place this September in Central London.

Bioceros has used its proprietary CHOBC® platform to generate a portfolio of cell lines producing biosimilar monoclonal antibodies. Dr Louis Boon has extended this expertise and developed a complete process toolbox to fit biosimilar CQAs. He continues to work on biosimilar development and innovative new molecular antibody entities which can be extended to GMP production and clinical testing.

In the run-up to his talk entitled “Spot and Process Modulation Technology to Reduce Cost of Goods (Cogs) for Biosimilar Development” SMi Group caught up with him to discuss industry developments and his upcoming presentation. From the answers provided, it is apparent that competitive pricing of biosimilar drugs will continue to be a major challenge for branded pharmaceuticals.

“

Currently discounts may be up to 70% although also lower discount % have been reported”

Bioceros Founder and Chief Scientific Officer

“Currently discounts may be up to 70% although also lower discount % have been reported. Price may even further decrease, when in similarity with small molecules clinical development, clinical development only involves phase I and no Phase III anymore. This will drive the development cost down considerably and consequently higher discounting may be applicable. Branded products may not be able to complete due to less optimal processes which were developed years ago using old technology.”

The full interview is available to read in the event [download centre](#).

The 8th annual Biosimilars & Biobetters conference will take place on 27th and 28th September at the Holiday Inn Kensington Forum in Central London. More information is available at www.biosimilars-europe.com



SMi's 8th annual event...
Biosimilars & Biobetters
Holiday Inn Kensington Forum,
London UK
27 - 28
SEPT
2017
www.biosimilars-europe.com
Biosimilars & Biobetters 2017

--end --

Contact Information: For media inquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk

For all other inquiries contact the team on Tel: +44 (0)20 7827 6000 or email events@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri
SMi Group
2078276000
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.